[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
About the Journal
Editorial Board
Aims & Scopes
Journal News
Articles archive::
All Issues
Current Issue
For Authors::
Submission Instruction
Submission Form
Peer review process
Ethical Consideration
For Reviewers::
Reviewers Section
Registration::
Registration Form
Contact us::
Contact Information
Indexing::
open access policy::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Registered in

AWT IMAGE

AWT IMAGE
..
:: Volume 13 - Supplement, Winter ::
aumj 2024, 13 - Supplement, Winter: 103-113 Back to browse issues page
Determination of key genes and cellular signaling pathways involved in the resistance of patients with diffuse large B-cell lymphoma to Helicobacter pylori eradication treatment
Mohammad-Moien Forghani-Ramandi1 , Arvin Najafi * 2
1- Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
2- Assistant Professor of Orthopedics, School of Medicine, Clinical Research Development Unit, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj, Iran
Abstract:   (932 Views)
Background: Diffuse large B-cell lymphoma is the most common invasive non-Hodgkin's lymphoma. There is a strong relationship between Helicobacter pylori infection and the occurrence of this malignancy. It has been seen that some patients with DLBCL in the early stages respond well to Helicobacter pylori eradication treatment, but others are resistant to it. Due to the lack of sufficient knowledge about the occurrence of this resistance, it is necessary to identify mechanisms of resistance.
Methods: The gene expression data of sensitive and resistant patients were obtained from GEO site. After determining the genes with altered expression, in order to identify the key genes, the protein interaction network was constructed and the important genes were filtered based on the network centrality indices. Finally, cellular signaling pathways associated with key genes were determined.
Results: CXCL8, EGFR, FN1, ICAM1, IL1B, TLR2, TLR4, TNF and VEGFA genes were identified as highly important genes according to the network analysis and the results obtained from the pathway enrichment analysis. Key genes showed a significant relationship with functions related to the regulation of immune cells activation.
Conclusion: The results obtained from this study show the significant role of cell functions related to surface receptors and also the regulation of immune cells activation in the occurrence of resistance to treatment. The genes and cellular pathways identified in this study can be used as therapeutic targets and biomarkers for diagnosis, determination of the appropriate treatment method for the patients and prognosis.
Keywords: Diffuse large B-cell lymphoma, DLBCL, Bioinformatics, Helicobacter pylori
Full-Text [PDF 1156 kb]   (315 Downloads)    
Type of Study: Research | Subject: Special
Received: 2023/06/24 | Accepted: 2023/08/26 | Published: 2024/02/28
References
1. Ghimire P, Wu GY, Zhu L. Primary gastrointestinallymphoma. World J Gastroenterol. Feb 142011;17(6):697-707. doi:10.3748/wjg.v17.i6.697 [DOI:10.3748/wjg.v17.i6.697]
2. Wang YG, Zhao LY, Liu CQ, et al. Clinicalcharacteristics and prognostic factors of primarygastric lymphoma: A retrospective study with 165cases. Medicine (Baltimore). Aug 2016;95(31):e4250.doi:10.1097/md.0000000000004250 [DOI:10.1097/MD.0000000000004250]
3. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organizationclassification of lymphoid neoplasms. Blood.May 19 2016;127(20):2375-90. doi:10.1182/blood-2016-01-643569 [DOI:10.1182/blood-2016-01-643569]
4. Violeta Filip P, Cuciureanu D, Sorina DiaconuL, Maria Vladareanu A, Silvia Pop C. MALTlymphoma: epidemiology, clinical diagnosis andtreatment. J Med Life. Jul-Sep 2018;11(3):187-193.doi:10.25122/jml-2018-0035 [DOI:10.25122/jml-2018-0035]
5. Mulalic E, Delibegovic S. An Aggressive Form ofMALT Lymphoma of the Stomach with PancreasInfiltration. Med Arch. Jun 2016;70(3):235-7.doi:10.5455/medarh.2016.70.235-237 [DOI:10.5455/medarh.2016.70.235-237]
6. Kuo SH, Yeh KH, Wu MS, et al. Helicobacterpylori eradication therapy is effective in thetreatment of early-stage H pylori-positive gastricdiffuse large B-cell lymphomas. Blood. May 242012;119(21):4838-44; quiz 5057. doi:10.1182/blood-2012-01-404194 [DOI:10.1182/blood-2012-01-404194]
7. Huang WT, Kuo SH, Kuo YC, Lin CW. miR-155-regulated mTOR and Toll-like receptor 5 in gastricdiffuse large B-cell lymphoma. Cancer Med. Feb2022;11(3):555-570. doi:10.1002/cam4.4466 [DOI:10.1002/cam4.4466]
8. Takahara T, Nakamura S, Tsuzuki T, Satou A. TheImmunology of DLBCL. Cancers (Basel). Jan 292023;15(3)doi:10.3390/cancers15030835 [DOI:10.3390/cancers15030835]
9. de Jong D, Enblad G. Inflammatory cells and immunemicroenvironment in malignant lymphoma. J InternMed. Dec 2008;264(6):528-36. doi:10.1111/j.1365-2796.2008.02032.x [DOI:10.1111/j.1365-2796.2008.02032.x]
10. Lam LT, Wright G, Davis RE, et al. Cooperativesignaling through the signal transducer and activatorof transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-celllymphoma. Blood. Apr 1 2008;111(7):3701-13.doi:10.1182/blood-2007-09-111948 [DOI:10.1182/blood-2007-09-111948]
11. Hirano T, Yasukawa K, Harada H, et al.Complementary DNA for a novel humaninterleukin (BSF-2) that induces B lymphocytesto produce immunoglobulin. Nature. Nov 6-121986;324(6092):73-6. doi:10.1038/324073a0 [DOI:10.1038/324073a0]
12. Rousset F, Garcia E, Defrance T, et al. Interleukin is a potent growth and differentiation factor foractivated human B lymphocytes. Proc Natl AcadSci U S A. Mar 1 1992;89(5):1890-3. doi:10.1073/pnas.89.5.1890 [DOI:10.1073/pnas.89.5.1890]
13. Voorzanger N, Touitou R, Garcia E, et al. Interleukin)IL(-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperativegrowth factors. Cancer Res. Dec 1 1996;56(23):5499-505.
14. Blay JY, Burdin N, Rousset F, et al. Seruminterleukin-10 in non-Hodgkin's lymphoma: aprognostic factor. Blood. Oct 1 1993;82(7):2169-74. [DOI:10.1182/blood.V82.7.2169.bloodjournal8272169]
15. Gupta M, Han JJ, Stenson M, et al. Elevated serumIL-10 levels in diffuse large B-cell lymphoma: amechanism of aberrant JAK2 activation. Blood.Mar 22 2012;119(12):2844-53. doi:10.1182/blood-2011-10-388538 [DOI:10.1182/blood-2011-10-388538]
16. Giachelia M, Voso MT, Tisi MC, et al. Interleukin-6plasma levels are modulated by a polymorphism inthe NF-κB1 gene and are associated with outcomefollowing rituximab-combined chemotherapy indiffuse large B-cell non-Hodgkin lymphoma. LeukLymphoma. Mar 2012;53(3):411-6. doi:10.3109/10428194.2011.621566 [DOI:10.3109/10428194.2011.621566]
17. Budakoti M, Panwar AS, Molpa D, et al. Micro-RNA: The darkhorse of cancer. Cell Signal. Jul2021;83:109995. doi:10.1016/j.cellsig.2021.109995 [DOI:10.1016/j.cellsig.2021.109995]
18. Jabłońska E, Białopiotrowicz E, Szydłowski M, Prochorec-Sobieszek M, Juszczyński P, Szumera-Ciećkiewicz A. DEPTOR is a microRNA-155target regulating migration and cytokine productionin diffuse large B-cell lymphoma cells. ExpHematol. Aug 2020;88:56-67.e2. doi:10.1016/j.exphem.2020.07.005 [DOI:10.1016/j.exphem.2020.07.005]
19. Fangazio M, Ladewig E, Gomez K, et al. Geneticmechanisms of HLA-I loss and immune escape indiffuse large B cell lymphoma. Proc Natl Acad Sci U SA. Jun 1 2021;118(22)doi:10.1073/pnas.2104504118 [DOI:10.1073/pnas.2104504118]
20. Raskov H, Orhan A, Christensen JP, Gögenur I.Cytotoxic CD8)+(T cells in cancer and cancerimmunotherapy. Br J Cancer. Jan 2021;124(2):359-367. doi:10.1038/s41416-020-01048-4 [DOI:10.1038/s41416-020-01048-4]
21. Reimann M, Schrezenmeier J, Richter-Pechanska P, et al. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-celllymphomas. Blood. May 20 2021;137(20):2785-2799. doi:10.1182/blood.2020005244 [DOI:10.1182/blood.2020005244]
22. Xu W, Berning P, Lenz G. Targeting B-cellreceptor and PI3K signaling in diffuse large B-celllymphoma. Blood. Sep 30 2021;138(13):1110-1119.doi:10.1182/blood.2020006784 [DOI:10.1182/blood.2020006784]
23. Davis RE, Ngo VN, Lenz G, et al. Chronic activeB-cell-receptor signalling in diffuse large B-celllymphoma. Nature. Jan 7 2010;463(7277):88-92.doi:10.1038/nature08638 [DOI:10.1038/nature08638]
Add your comments about this article
Your username or Email:

CAPTCHA

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Forghani-Ramandi M, Najafi A. Determination of key genes and cellular signaling pathways involved in the resistance of patients with diffuse large B-cell lymphoma to Helicobacter pylori eradication treatment. aumj 2024; 13 :103-113
URL: http://aums.abzums.ac.ir/article-1-1797-en.html
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 13 - Supplement, Winter Back to browse issues page
نشریه دانشگاه علوم پزشکی البرز Alborz University Medical Journal
Persian site map - English site map - Created in 0.05 seconds with 39 queries by YEKTAWEB 4660